Progress in SLE with new mRNA CAR-T cell Trial

Save

Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial. 

Efficacy of Biologics in Patients with Chronic KIdney Disease

Save

PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?

Save

Cost-Effectiveness of Biosimilars vs Leflunomide

Save

An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide.

ICYMI: Can Mycophenolate be Stopped in Stable SLE?

Save

In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.

ICYMI: Dead Words Eulogy

Save

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?

Save

Imaging is often instrumental in diagnosing and staging patients diagnosed with giant cell arteritis. A new study compared the diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography and Magnetic Resonance Imaging in patients suspected of giant cell arteritis and found the CDUS had a numerically higher sensitivity (that was not statistically superior to other modalities).

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

Save

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Save

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.

ICYMI: 9 Facts about Leflunomide

Save

Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.

ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis

Save

An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

Save

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

ICYMI: JAMA: SLE Review

Save

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

ICYMI: BSR Guideline on Management of Sjogren’s Syndrome

Save

Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and recommendations for the management of children and adolescents with SD. This article reviews the data and recommendations stemming from 19 questions on SD care.

Review of Amyloidosis

Save

The New England Journal of Medicine has published a review of systemic amyloidosis.